Cutaneous fibrosis induced by docetaxel
- Resource Type
- Authors
- B. S. Ajaikumar; Mark G. Cleveland M.D.; Rohini Reganti
- Source
- Cancer. 88:1078-1081
- Subject
- Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Pathology
business.industry
medicine.medical_treatment
Cancer
medicine.disease
Scleroderma
Taxoid
chemistry.chemical_compound
Paclitaxel
chemistry
Docetaxel
Fibrosis
Internal medicine
Carcinoma
medicine
business
medicine.drug
- Language
- ISSN
- 1097-0142
0008-543X
BACKGROUND Docetaxel is a taxoid antineoplastic agent approved for use in the treatment of metastatic breast carcinoma. The current study reports an unusual case of generalized cutaneous fibrosis in a 39-year-old white female after treatment with 18 cycles of docetaxel for metastatic breast carcinoma. METHODS Cutaneous fibrosis represents a rare and unique reaction associated with the cyclic use of docetaxel. The reaction is manifested by a distinct sequence of events involving pronounced edema followed by the rapid development of cutaneous fibrosis in dependent areas. RESULTS Cessation of therapy results in dramatic reversal of the fibrotic process. CONCLUSIONS This case report further substantiates the belief that docetaxel represents one of a very limited number of agents that appear capable of giving rise to scleroderma-like features. Cancer 2000;88:1078–81. © 2000 American Cancer Society.